Trulieve's Schedule III Milestone Arrives as a New York Listing Reshapes Its Corporate Identity
Published on 08/23/2026 at 18:22 | Redaktion boerse-global.de
The regulatory calendar at Trulieve has been unusually crowded this summer, and the latest development carries real weight: all 207 of the company's medical cannabis dispensaries are now registered with the US Drug Enforcement Administration, with inspections complete. The registrations follow marijuana's reclassification to Schedule III, which took effect in April 2026 — a shift that gives the company a firmer legal footing as it pushes deeper into the American medical market.
The DEA clearance lands at a moment when Trulieve is fundamentally redrawing its corporate map. On 11 August, the company finished relocating its legal home from British Columbia to Delaware, after shareholders backed the move at a special meeting on 5 August and the Supreme Court of British Columbia granted final court approval on 10 August. Barely a week later, on 18 August, founder and CEO Kim Rivers joined her leadership team to ring the closing bell at the New York Stock Exchange — a ceremony marking the company's June debut as the first US cannabis firm to list on the exchange. Shares have traded under the ticker NYSE: TRLV since 10 June.
A Medical Business Carrying More Weight
The DEA registration was set in motion in early August, when Trulieve filed applications covering its state-licensed operations and flagged potential growth opportunities in Georgia and Texas. With the paperwork now complete, the company has cleared a significant hurdle for expanding its medical footprint. That segment has been doing the heavy lifting lately: pro-forma pure-play medical revenue reached $222.3 million in the second quarter, up from $214 million in the first.
The broader numbers, released on 7 August, paint a more complicated picture. Adjusted earnings per share came in at $0.11, beating the consensus estimate of $0.08, while revenue of $271 million fell just short of the $272.21 million analysts had penciled in. Retail accounted for 94% of sales, and gross margin held at 60%. Adjusted EBITDA reached $98 million, with free cash flow of $32 million.
Should investors sell immediately? Or is it worth buying Trulieve?
The bottom line, however, was dragged down by a net loss of $406 million, or $2.10 per share, reflecting a $407 million charge tied to the deconsolidation of Harvest operations in states with mixed medical and adult-use markets. That accounting shift also prompted Trulieve to trim its full-year 2026 operating cash flow guidance to at least $225 million, down from a prior target of $250 million. Management reaffirmed that outlook on the 9 August earnings call, alongside capital expenditure guidance of $60 million to $80 million. The company ended the first half with $325 million in liquidity, supported by $109 million in operating cash flow over the six-month period.
Buybacks, Insider Sales, and a Slimmed-Down Finance Team
Alongside the quarterly report, Trulieve unveiled a share repurchase program of up to $50 million, or 8,495,038 shares, without disclosing any buybacks executed to date. The buyback arrives against a backdrop of persistent insider selling: seven insider sales have occurred over the past six months, with no purchases. Rivers said in June she would wind down her automatic selling plan in August, and a first tranche of 1,699,007 shares has already changed hands. Over the past 90 days, insider sales totaled roughly 1.7 million shares worth $14.7 million, according to media reports.
The finance department also underwent a quiet restructuring in late June, with the standalone chief accounting officer role eliminated and CFO Jan Reese absorbing the top accounting responsibilities.
What Analysts Make of It All
Cantor Fitzgerald reaffirmed an Overweight rating on 7 August with a price target of $15.00, a vote of confidence issued the same day as the earnings release. The endorsement underscores a degree of analyst support even as the company navigates the Harvest deconsolidation and a shifting regulatory landscape.
For investors, the past few weeks have delivered a study in contrasts: structural wins on the regulatory and corporate front, paired with a loss-heavy income statement and persistent insider selling. The DEA registrations, the NYSE listing, and the Delaware redomiciliation collectively signal a company cementing its position in the US market. Whether the operational metrics can catch up to the symbolism is the question that will define the coming quarters.
Ad
Trulieve Stock: New Analysis - 23 August
Fresh Trulieve information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
